155 related articles for article (PubMed ID: 30176814)
21. Systematically higher Ki67 scores on core biopsy samples compared to corresponding resection specimen in breast cancer: a multi-operator and multi-institutional study.
Acs B; Leung SCY; Kidwell KM; Arun I; Augulis R; Badve SS; Bai Y; Bane AL; Bartlett JMS; Bayani J; Bigras G; Blank A; Buikema H; Chang MC; Dietz RL; Dodson A; Fineberg S; Focke CM; Gao D; Gown AM; Gutierrez C; Hartman J; Kos Z; Lænkholm AV; Laurinavicius A; Levenson RM; Mahboubi-Ardakani R; Mastropasqua MG; Nofech-Mozes S; Osborne CK; Penault-Llorca FM; Piper T; Quintayo MA; Rau TT; Reinhard S; Robertson S; Salgado R; Sugie T; van der Vegt B; Viale G; Zabaglo LA; Hayes DF; Dowsett M; Nielsen TO; Rimm DL;
Mod Pathol; 2022 Oct; 35(10):1362-1369. PubMed ID: 35729220
[TBL] [Abstract][Full Text] [Related]
22. Ki67 expression in invasive breast cancer: the use of tissue microarrays compared with whole tissue sections.
Muftah AA; Aleskandarany MA; Al-Kaabi MM; Sonbul SN; Diez-Rodriguez M; Nolan CC; Caldas C; Ellis IO; Rakha EA; Green AR
Breast Cancer Res Treat; 2017 Jul; 164(2):341-348. PubMed ID: 28478613
[TBL] [Abstract][Full Text] [Related]
23. Prognostic potential of automated Ki67 evaluation in breast cancer: different hot spot definitions versus true global score.
Robertson S; Acs B; Lippert M; Hartman J
Breast Cancer Res Treat; 2020 Aug; 183(1):161-175. PubMed ID: 32572716
[TBL] [Abstract][Full Text] [Related]
24. Prognostic comparison of the proliferation markers (mitotic activity index, phosphohistone H3, Ki67), steroid receptors, HER2, high molecular weight cytokeratins and classical prognostic factors in T₁₋₂N₀M₀ breast cancer.
Gudlaugsson E; Klos J; Skaland I; Janssen EA; Smaaland R; Feng W; Shao Z; Malpica A; Baak JP
Pol J Pathol; 2013 Apr; 64(1):1-8. PubMed ID: 23625593
[TBL] [Abstract][Full Text] [Related]
25. Comparison of central laboratory assessments of ER, PR, HER2, and Ki67 by IHC/FISH and the corresponding mRNAs (ESR1, PGR, ERBB2, and MKi67) by RT-qPCR on an automated, broadly deployed diagnostic platform.
Wu NC; Wong W; Ho KE; Chu VC; Rizo A; Davenport S; Kelly D; Makar R; Jassem J; Duchnowska R; Biernat W; Radecka B; Fujita T; Klein JL; Stonecypher M; Ohta S; Juhl H; Weidler JM; Bates M; Press MF
Breast Cancer Res Treat; 2018 Nov; 172(2):327-338. PubMed ID: 30120700
[TBL] [Abstract][Full Text] [Related]
26. Multi-level gene expression signatures, but not binary, outperform Ki67 for the long term prognostication of breast cancer patients.
Tobin NP; Lindström LS; Carlson JW; Bjöhle J; Bergh J; Wennmalm K
Mol Oncol; 2014 May; 8(3):741-52. PubMed ID: 24630985
[TBL] [Abstract][Full Text] [Related]
27. Quantitative tumor heterogeneity assessment on a nuclear population basis.
Wessel Lindberg AS; Conradsen K; Larsen R; Friis Lippert M; Røge R; Vyberg M
Cytometry A; 2017 Jun; 91(6):574-584. PubMed ID: 28141908
[TBL] [Abstract][Full Text] [Related]
28. ki67 nuclei detection and ki67-index estimation: a novel automatic approach based on human vision modeling.
Barricelli BR; Casiraghi E; Gliozzo J; Huber V; Leone BE; Rizzi A; Vergani B
BMC Bioinformatics; 2019 Dec; 20(1):733. PubMed ID: 31881821
[TBL] [Abstract][Full Text] [Related]
29. Implementation of Digital Image Analysis in Assessment of Ki67 Index in Breast Cancer.
Vanderschelden RK; Jerome JA; Gonzalez D; Seigh L; Carter GJ; Clark BZ; Elishaev E; Louis Fine J; Harinath L; Jones MW; Villatoro TM; Soong TR; Yu J; Zhao C; Hartman D; Bhargava R
Appl Immunohistochem Mol Morphol; 2024 Jan; 32(1):17-23. PubMed ID: 37937544
[TBL] [Abstract][Full Text] [Related]
30. Sequential immunohistochemistry and virtual image reconstruction using a single slide for quantitative KI67 measurement in breast cancer.
Serna G; Simonetti S; Fasani R; Pagliuca F; Guardia X; Gallego P; Jimenez J; Peg V; Saura C; Eppenberger-Castori S; Ramon Y Cajal S; Terracciano L; Nuciforo P
Breast; 2020 Oct; 53():102-110. PubMed ID: 32707454
[TBL] [Abstract][Full Text] [Related]
31. Long-term outcome and prognostic value of Ki67 after perioperative endocrine therapy in postmenopausal women with hormone-sensitive early breast cancer (POETIC): an open-label, multicentre, parallel-group, randomised, phase 3 trial.
Smith I; Robertson J; Kilburn L; Wilcox M; Evans A; Holcombe C; Horgan K; Kirwan C; Mallon E; Sibbering M; Skene A; Vidya R; Cheang M; Banerji J; Morden J; Sidhu K; Dodson A; Bliss JM; Dowsett M
Lancet Oncol; 2020 Nov; 21(11):1443-1454. PubMed ID: 33152284
[TBL] [Abstract][Full Text] [Related]
32. Digital imaging in the immunohistochemical evaluation of the proliferation markers Ki67, MCM2 and Geminin, in early breast cancer, and their putative prognostic value.
Joshi S; Watkins J; Gazinska P; Brown JP; Gillett CE; Grigoriadis A; Pinder SE
BMC Cancer; 2015 Jul; 15():546. PubMed ID: 26205655
[TBL] [Abstract][Full Text] [Related]
33. Unsupervised domain adaptive tumor region recognition for Ki67 automated assisted quantification.
He Q; Liu Y; Pan F; Duan H; Guan J; Liang Z; Zhong H; Wang X; He Y; Huang W; Guan T
Int J Comput Assist Radiol Surg; 2023 Apr; 18(4):629-640. PubMed ID: 36371746
[TBL] [Abstract][Full Text] [Related]
34. Quantum dots-based double imaging combined with organic dye imaging to establish an automatic computerized method for cancer Ki67 measurement.
Wang LW; Qu AP; Liu WL; Chen JM; Yuan JP; Wu H; Li Y; Liu J
Sci Rep; 2016 Feb; 6():20564. PubMed ID: 26839163
[TBL] [Abstract][Full Text] [Related]
35. Ki67 proliferation in core biopsies versus surgical samples - a model for neo-adjuvant breast cancer studies.
Romero Q; Bendahl PO; Klintman M; Loman N; Ingvar C; Rydén L; Rose C; Grabau D; Borgquist S
BMC Cancer; 2011 Aug; 11():341. PubMed ID: 21819622
[TBL] [Abstract][Full Text] [Related]
36. A Comparison of Visual Assessment and Automated Digital Image Analysis of Ki67 Labeling Index in Breast Cancer.
Zhong F; Bi R; Yu B; Yang F; Yang W; Shui R
PLoS One; 2016; 11(2):e0150505. PubMed ID: 26928407
[TBL] [Abstract][Full Text] [Related]
37. Comparison of the effect of different techniques for measurement of Ki67 proliferation on reproducibility and prognosis prediction accuracy in breast cancer.
Gudlaugsson E; Skaland I; Janssen EA; Smaaland R; Shao Z; Malpica A; Voorhorst F; Baak JP
Histopathology; 2012 Dec; 61(6):1134-44. PubMed ID: 22963617
[TBL] [Abstract][Full Text] [Related]
38. The Genomic Grade Assay Compared With Ki67 to Determine Risk of Distant Breast Cancer Recurrence.
Ignatiadis M; Azim HA; Desmedt C; Veys I; Larsimont D; Salgado R; Lyng MB; Viale G; Leyland-Jones B; Giobbie-Hurder A; Kammler R; Dell'Orto P; Rothé F; Laïos I; Ditzel HJ; Regan MM; Piccart M; Michiels S; Sotiriou C
JAMA Oncol; 2016 Feb; 2(2):217-24. PubMed ID: 26633571
[TBL] [Abstract][Full Text] [Related]
39. Correlative studies of the Breast Cancer Index (HOXB13/IL17BR) and ER, PR, AR, AR/ER ratio and Ki67 for prediction of extended endocrine therapy benefit: a Trans-aTTom study.
Sgroi DC; Treuner K; Zhang Y; Piper T; Salunga R; Ahmed I; Doos L; Thornber S; Taylor KJ; Brachtel E; Pirrie S; Schnabel CA; Rea D; Bartlett JMS
Breast Cancer Res; 2022 Dec; 24(1):90. PubMed ID: 36527133
[TBL] [Abstract][Full Text] [Related]
40. Gene expression profiling revealed MCM3 to be a better marker than Ki67 in prognosis of invasive ductal breast carcinoma patients.
Zhao Y; Wang Y; Zhu F; Zhang J; Ma X; Zhang D
Clin Exp Med; 2020 May; 20(2):249-259. PubMed ID: 31980982
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]